DiamiR

Executive Summary

DiamiR is a molecular diagnostics company pioneering minimally invasive blood tests for early detection and monitoring of neurodegenerative and neurodevelopmental disorders. Its proprietary platform analyzes brain-enriched microRNA biomarkers in plasma to capture signatures of brain and synaptic health, enabling earlier intervention for conditions such as Alzheimer's, Parkinson's, and autism spectrum disorder. Founded in 2014 and headquartered in Bala Cynwyd, Pennsylvania, the company addresses a critical unmet need for accessible, scalable diagnostic tools in neurology. With the global burden of neurodegenerative diseases rising, DiamiR's approach has the potential to transform screening, diagnosis, and therapeutic monitoring. The company remains in a development stage, with no disclosed funding or valuation, yet its technology has shown early promise in published studies. The company's trajectory hinges on advancing its pipeline through clinical validation and securing strategic partnerships or regulatory endorsements to accelerate commercialization.

Upcoming Catalysts (preview)

• Q4 2026Publication of clinical validation data for Alzheimer's disease blood test60% success
• Q2 2027FDA Breakthrough Device Designation for a lead indication40% success
• Q3 2027Strategic partnership or licensing agreement with a major diagnostics company30% success